1K9 Stock Overview
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CareDx, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.14 |
| 52 Week High | US$11.50 |
| 52 Week Low | US$4.58 |
| Beta | 1.45 |
| 1 Month Change | -25.58% |
| 3 Month Change | -20.62% |
| 1 Year Change | -2.14% |
| 3 Year Change | -88.66% |
| 5 Year Change | -72.67% |
| Change since IPO | 5.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1K9 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.6% | 0.8% | 1.2% |
| 1Y | -2.1% | -24.4% | 2.0% |
Return vs Industry: 1K9 exceeded the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 1K9 underperformed the German Market which returned 2% over the past year.
Price Volatility
| 1K9 volatility | |
|---|---|
| 1K9 Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1K9's share price has been volatile over the past 3 months.
Volatility Over Time: 1K9's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 639 | John Hanna | caredx.com |
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software.
CareDx, Inc Fundamentals Summary
| 1K9 fundamental statistics | |
|---|---|
| Market cap | €365.92m |
| Earnings (TTM) | -€177.88m |
| Revenue (TTM) | €262.05m |
1.4x
P/S Ratio-2.1x
P/E RatioIs 1K9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1K9 income statement (TTM) | |
|---|---|
| Revenue | US$280.32m |
| Cost of Revenue | US$102.00m |
| Gross Profit | US$178.33m |
| Other Expenses | US$368.61m |
| Earnings | -US$190.28m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.67 |
| Gross Margin | 63.61% |
| Net Profit Margin | -67.88% |
| Debt/Equity Ratio | 0% |
How did 1K9 perform over the long term?
See historical performance and comparison